Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 52-Week High – Here’s Why

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) hit a new 52-week high on Thursday . The company traded as high as $12.72 and last traded at $12.64, with a volume of 3058268 shares. The stock had previously closed at $12.33.

Analysts Set New Price Targets

Several brokerages have recently commented on AMRX. JPMorgan Chase & Co. raised their price objective on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Piper Sandler reiterated an “overweight” rating and set a $13.00 target price (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research report on Friday, October 31st. Barclays began coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They issued an “overweight” rating and a $15.00 price target for the company. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.50.

Amneal Pharmaceuticals Stock Performance

The stock’s 50 day simple moving average is $11.44 and its 200 day simple moving average is $9.75. The firm has a market cap of $3.95 billion, a P/E ratio of 628.06 and a beta of 1.36.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. Amneal Pharmaceuticals had a net margin of 0.20% and a negative return on equity of 185.60%. The firm had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Ted C. Nark sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the transaction, the director owned 291,029 shares in the company, valued at $3,410,859.88. This trade represents a 14.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Nikita Shah sold 131,856 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $11.92, for a total value of $1,571,723.52. Following the transaction, the executive vice president directly owned 146,403 shares in the company, valued at approximately $1,745,123.76. The trade was a 47.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 231,856 shares of company stock valued at $2,743,724. Company insiders own 26.56% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

Several institutional investors have recently made changes to their positions in AMRX. Comerica Bank lifted its position in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares in the last quarter. Exchange Traded Concepts LLC purchased a new stake in Amneal Pharmaceuticals in the 3rd quarter valued at about $31,000. Focus Partners Wealth bought a new position in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $42,000. Advisory Services Network LLC purchased a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $50,000. Finally, Bellevue Group AG bought a new position in shares of Amneal Pharmaceuticals in the third quarter valued at approximately $79,000. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.